Evaluation of Pharmacokinetic Profile of GLP-1 Receptor Agonist Exenatide in Type 2 Diabetes Experimental Model

The study's objective was to evaluate Exenatide for treating Type 2 Diabetic Mellitus (T2DM) in an animal model. The safety profile and dose determination for the in vivo antidiabetic study were established through an acute toxicity study conducted by OECD guideline 425. The plasma levels of exenatide were studied using a pharmacokinetic model in rats. After Exenatide were given to the rats, their behavior, biochemical, and hematological characteristics were tested. Animals were administered Streptozotocin (STZ, 60 mg/mL, i/p) to induce diabetes. Blood glucose levels above 250 mg/dL were diagnostic of diabetes in animals. The drug was non-toxic in toxicity investigation. Results showed that administration of drug did not cause any significant change in behavioral, biochemical, or hematological markers. It was revealed that Exenatide significantly lowered blood glucose levels in diabetic animals. The results of the study indicated that Exenatide has the potential to be utilized as an alternative antidiabetic medicine against Type 2 Diabetes.